FDA approves first quadrivalent intradermal influenza vaccine
the ONA take:
Sanofi Pasteur has announced that the U.S. Food and Drug Administration (FDA) has approved Fluzone Intradermal Quadrivalent vaccine. A trivalent formulation of the vaccine has been available for 3 years, but the quadrivalent formulation will help to protect against four strains of influenza rather than three.
The vaccine is approved for adults aged 18 to 64 years for the prevention of infection by influenza A and B subtypes. The trivalent vaccine protects against two influenza A subtypes and only one influenza B subtype, but it is influenza B that is a common cause of morbidity and morality associated with influenza.
The most common adverse effects observed in clinical trials were erythema, headache, induration at the injection site, malaise, myalgia, pain, pruritus, and swelling. These reactions typically occurred within 3 days of vaccination and were mild to moderate in severity.
In addition, the intradermal vaccines is equally as effective as an intramuscular flu shot. Like other flu shots, the Fluzone Intradermal Quadrivalent vaccine should not be administered to patients with egg allergies or to anyone who has experienced a hypersensitivity reaction to a previous influenza vaccine.
The FDA has approved Fluzone Intradermal Quadrivalent vaccine for influenza.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|